Squamous cell carcinoma of the esophagus |
|
Gastric cancers |
|
Gastroesophageal junction adenocarcinoma |
|
Pancreatic cancers | ICI: pembrolizumab, atezolizumab, and Ipilimumab. Vaccine-based immunotherapy: clinical trials ongoing for a combination of GVAX+CRS-207±nivolumab.* Indoleamine 2,3-dioxygenase inhibitor: indoximod. CCR2/CCL2 signaling pathway inhibitor: clinical trials ongoing for PF-04136309.
|
Hepatobiliary cancers |
ICI: nivolumab showed promising results, clinical trials ongoing for pembrolizumab, tremelimumab, ipilimumab, atezolizumab, avelumab and durvalumab. Vaccine-based immunotherapy: HEPAVAC project ongoing. Adoptive T-cell transfer: under investigation.
|
Colorectal cancers |
ICIs: pembrolizumab and nivolumab. Vaccine-based immunotherapy: clinical trial ongoing for talimogene laherparepvec local injection vaccine+atezolizumab. Adoptive T-cell transfer: chimeric antigen receptor T-cell therapy.
|